Marinomed Biotech AG confirmed its financial outlook for the fiscal year 2022: The Company expects continued growth of Carragelose revenues and a slight increase in R&D expenses, and consequently an operating loss for 2022. Marinomed plans to reach operating profitability in the medium term.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
16.2 EUR | -0.61% | -4.42% | -44.52% |
04-16 | Transcript : Marinomed Biotech AG, 2023 Earnings Call, Apr 16, 2024 | |
04-16 | Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-44.52% | 27.27M | |
-3.15% | 89.69B | |
+3.95% | 41.34B | |
-10.51% | 33.72B | |
+60.08% | 26.11B | |
-20.09% | 14.63B | |
-8.92% | 12.84B | |
-11.46% | 11.66B | |
-43.05% | 11.52B | |
+3.97% | 8.92B |
- Stock Market
- Equities
- MARI Stock
- News Marinomed Biotech AG
- Marinomed Biotech AG Confirms Financial Outlook for the Fiscal Year 2022